Propranolol and Other Beta-Blockers
Also known by these names
- Angilol
- Ciplar
- Inderal
- Syprol
- Hemangeol (special oral formulation for the treatment of infantile hemangioma, or vascular tumors)
|
Key Points
- Before using this therapy, consult your oncology team about interactions with other treatments and therapies. Also make sure this therapy is safe for use with any other medical conditions you may have.
- Propranolol is a drug approved by the FDA for several diseases and conditions.
- It’s used off-label in cancer treatment.
- BCCT sees propranolol as an interesting and promising drug and is impressed with the early evidence to support re-purposing its use in cancer.
- Laboratory and clinical effects of propranolol in cancer treatment include inhibiting cancer cell proliferation, decreasing cancer cell migration and invasion, increasing cancer cell death, and inhibiting the growth of blood vessels to feed tumors.
- Propranolol shows promise in enhancing the effectiveness of conventional treatments, boosting the immune system’s cancer-fighting mechanisms, reducing metastases, extending survival, and reducing symptoms.
- Propranolol may also reduce stress and its cancer-promoting effects.
- Propranolol is generally safe and usable long-term, although several cautions and interactions are noted.
|
Authors
 Laura Pole, RN, MSN, OCNS, BCCT Senior Researcher
Read more Ms. Pole is an oncology clinical nurse specialist who has been providing integrative oncology clinical care, navigation, consultation and education services for more than 30 years. View profile.
 Nancy Hepp, MS, BCCT Project Manager
Read more Ms. Hepp is a science researcher and communicator who has been writing and editing educational content on varied health topics for more than 20 years. View profile. Last updated September 10, 2021.
|
Propranolol is a beta blocker (non-selective beta-adrenergic receptor antagonist) being used off-label for cancer treatment by some integrative oncologists. Off-label use is a drug’s application for a disease or condition that has not yet received FDA approval. Every US state allows for drugs to be used off-label as long as there is enough evidence to support its use.
Most of the human evidence in cancer to date is from case reports, but a number of clinical trials for several cancers are in progress.
Read more
The Cancer Prevention and Treatment Fund recommends that patients already taking beta blockers for a heart condition should continue use if they are also diagnosed with cancer. However, some caution against use only in cancer until stronger evidence from controlled clinical trials shows its efficacy.
Some research suggest that people not already using beta blockers who are diagnosed with non-small cell lung cancer or early breast cancer may want to ask their healthcare providers whether to take beta blockers for two days before and three days after cancer surgery.
Treating the Cancer
Working against cancer growth or spread, improving survival, or working with other treatments or therapies to improve their anticancer action
Clinical Evidence
An extensive review in 2016 found proprnolol exhibits anti-metastatic effects in breast and ovarian cancers. Evidence particularly indicates that propranolol works at multiple points in the metastatic cascade, especially in the setting of the post-surgical wound response (see more in How It Works at right).
Impacts on Survival
Read more
- Prolonged survival of cancer patients with use, especially patients with early-stage cancer treated primarily with surgery
- Angiosarcoma: Extended progression-free and overall survival among seven patients with advanced/metastatic/recurrent angiosarcoma
- Breast cancer:
- Mixed results regarding survival:
- Improved survival and decreased risk of breast cancer metastasis among postmenopausal women undergoing surgery for early primary triple-negative breast cancer
- Reduced breast cancer progression and mortality in some reviews
- Reduced breast cancer deaths but not overall mortality in one meta-analysis
- No survival advantage in other large pooled analyses
- Fewer metastatic biomarkers among people with early-stage breast cancer with 11 days of treatment with propranolol and a COX-2 inhibitor (etodolac), beginning five days before surgery in a small RTC
- Reduced toxicity to the heart and improved survival in female breast cancer patients undergoing trastuzumab/anthracycline treatment.
- Lower markers of cancer progression and immune activation against tumor cells among people with early-stage surgically resectable breast cancer with one week of beta-blocker use before surgery in a small RCT
- Lung cancer:
- Better distant metastasis-free survival among people with non-small-cell lung cancer receiving definitive radiotherapy with use of beta blockers in a mid-sized observational study
- No effect on survival among people with lung cancer with use of beta blockers either before or after diagnosis in a large observational study
- Ovarian cancer:
- Substantial (doubling or more) of overall survival among women with epithelial ovarian cancer with use of non-selective beta blockers during chemotherapy compared to no use of beta blockers or use of selective beta blocker in a large observational study
- 54% lower mortality among women with epithelial ovarian cancer undergoing cytoreductive surgery followed by platinum-based chemotherapy with use of beta blockers for more than six months in a mid-sized observational study
- reviews have concluded that beta blockers, especially nonselective beta blockers, provided a significant survival advantage, while no benefit was found with selective beta blockers
- Pancreatic cancer: Increased progression-free survival when adding propranolol/etodolac (a nonsteroidal anti-inflammatory drug, or NSAID) to treatment with gemcitabine and albumin-bound (nab) paclitaxel in a small study
- Prostate cancer: No decreased risk of mortality either from prostate cancer or from all causes among men newly diagnosed with non-metastatic prostate cancer
Reduced Metastasis
Read more
- Lower recurrence among people with stage 2 breast cancer (but not stage 3), but no better survival, with use of beta blockers at the time of surgery in a large observational study
- A 2016 review suggested that propranolol be added to standard of care for nonmetastatic cancers as a strategy to reduce the rate of metastasis.
Enhancer of Conventional Treatments
Read more
- Increased sensitivity of some cancers to certain chemotherapy drugs with propranolol; use increased the effectiveness of 5-FU and paclitaxel in breast cancer treatment
- Increased effectiveness of radiotherapy as well as chemoradiotherapy combinations with propranolol in case studies
Lab and Animal Evidence
How It Works
Propranolol seems to exert its anticancer activity in several ways:
- Inhibiting cancer cell proliferation
- Decreasing cancer cell migration and invasion
- Causing cell death (apoptosis)
- Inhibiting growth of new blood vessels (angiogenesis)
|
Read more
A 2016 comprehensive review of propranolol as an anticancer agent found evidence for its use in a number of cancers:
Anticancer Activity
In lab, animal and human studies and in clinical data, evidence suggests that propranolol has potent anticancer effects. An extensive review in 2016 found these effects:
- Interferes with cancer cell growth and invasion, reducing proliferation and increasing cell death (apoptosis)
- Reduces tumor angiogenesis (development of new blood vessels)
Beta blockers sensitized ovarian cancer cells to chemotherapeutic agents, enhancing chemotherapy effects in preclinical studies.
Propranolol decreased proliferation, migration, invasion and metastasis in preclinical studies when used with metformin.
Propranolol and Surgery
Surgery may be linked to an increased risk of metastasis. The flood of stress hormones that often accompany surgery may be one contributor to this increase. Some beta blockers reduce the stress response and may therefore lead to lower risk of metastasis. Preliminary evidence supports this line of thinking.
Read more One study found that propranolol administered peri-operatively may reduce the establishment of brain metastases in patients with triple-negative breast cancer. A 2016 review suggested that propranolol be added to standard of care for nonmetastatic cancers as a strategy to reduce the rate of metastasis.
Propranolol also appears to work synergistically with a COX-2/PGE2 inhibitor such as ketorolac or etodolac. A 2016 study suggests focusing further study of this effect on cancers in which post-surgical distant metastases are frequent.
|
Managing Side Effects and Promoting Wellness
Managing or relieving side effects or symptoms, reducing treatment toxicity, supporting quality of life or promoting general well-being
Read more
- Reduced risk of heart failure and markers of cardiotoxicity in patients undergoing anthracycline chemotherapy, especially with carvedilol use.
- Reduced cardiotoxicity and improved survival in female breast cancer patients undergoing trastuzumab/anthracycline treatment.
- Reduced emotional distress in newly diagnosed cancer patients.
- Reduced pain and neuropathy and increased weight gain in a small study of people with locally advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel with the addition of a propranolol/etodolac regimen
- Reduced resting energy expendituren in a small study of cancer patients with progressive weight loss due to solid malignant tumors
- Reduced levels of emotional distress, including intrusive thoughts related to cancer diagnosis, with propranolol in a study of women with breast cancer or colorectal cancer
Reducing Risk
Reducing the risk of developing cancer or the risk of recurrence
Clinical Evidence
Read more
Reduced risks of cancers of the head and neck, esophagus, stomach, colon and prostate.
Decreased risk of breast cancer-related recurrence among postmenopausal women with early primary triple-negative breast cancer, but no overall reduced risk of recurrence.
- Substantially lower recurrence of melanoma in a small prospective study
Optimizing Your Terrain
- Reduced effects of psychological stress on primary tumor growth with propranolol
- Reduced tumor-promoting effects of catecholamines (hormones produced by the adrenal glands) in retrospective clinical studies with ovarian cancer
- Enhanced immune system cancer-fighting mechanisms, such as increasing the ability of certain immune cells (macrophages) to consume cancer cells by a process called phagocytosis
Stress and Beta Blockers
Chronic stress triggers a chain of internal events that protects cancer cells from automatic destruction when they break away from the primary tumor. Increased levels of epinephrine and norepinephrine (stress hormones) allow malignant cells to safely leave the primary tumor, avoid cell death, and proceed to the next step of metastasis and progression.
When norepinephrine contacts the beta-adrenergic (ADRB) receptor on tumor cells, it activates Src, a gene which regulates cancer cell survival proteins. This activation causes a chain reaction inside cells that promotes cell survival, mobility, invasion of neighboring tissue and creation of new blood vessels to supply the tumor. Beta blockers plug the ADRB receptor and prevent activation by norepinephrine and other hormones.
Read more
- Propranolol inhibited the “priming effect” of repeated social disruption stress, in which natural killer (NK) cells increase in both numbers and cell-killing activity..
- Effects in ovarian cancer:
- A 2015 study found that stress hormones fuel progression of ovarian and other cancers and that beta blockers might be a new way to counter that effect. Findings:
- Stressing mice with ovarian cancer causes their tumors to grow and spread more quickly. Propranolol can block this effect.
- Effects with breast cancer:
- Propranolol reduced activity of hexokinase-2, an enzyme important for tumor metabolism.
- Salbutamol inhibited invasion of tumor cells and decreased expression of pro-metastatic genes in cell studies.
- Propranolol blocked the norepinephrine-induced migration of prostate cancer cells in animal studies.
Access
Propranolol is available by prescription as both standard and extended-release tablets, an oral solution, and an IV injection. It is available globally in generic form. Estimated cash price for sixty 40-mg tablets ranges from about $40 to $75. Significant discounts are available using prescription drug discount apps such as GoodRX.
Cautions
Propranolol generally has low toxicity and can be used for many years in long-term treatment. However, some cautions should be heeded:
Read more
- Calcium-channel blocking drugs: Caution is warranted using propranolol with calcium-channel blocking drugs, particularly IV verapamil, in patients with severe cardiomyopathy, congestive heart failure, or recent myocardial infarction (heart attack) due to the negative inotropic and chronotropic action of these drugs (actions affecting the force of contractions or heart rate and rhythm).
- Sudden cessation of use is not advised, especially in ischemic heart disease. In this case, gradually taper the dose.
Adverse Events / Side Effects
| Common |
Less common |
Rare |
|
|
|
- Heart failure
- Heart block
- Hypotension (low blood pressure)
- Worsening of symptoms of psoriasis, asthma and psychosis
|
Contraindications / Do Not Use If
Patients with these conditions should not use propranolol:
- Hypotension (low blood pressure)
- Asthma
- Uncontrolled heart failure
- Severe peripheral artery disease
- Metabolic acidosis
- Cardiogenic shock
Use is not recommended in pregnancy and during lactation.
Interactions
Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) to share with your doctor and pharmacist. Do not start, stop or change the dosage of any medicines without your doctor's approval.
A study involving both animal and human cells demonstrated that two drugs that stimulate the beta adrenergic receptor, isoprenaline and salbutamol, unexpectedly inhibited breast cancer and that propranolol reversed this inhibition.
Specific Drug Interactions
Some products that may interact with this drug:
- Alpha blockers (such as prazosin)
- Aluminum hydroxide
- Anticholinergics (such as atropine, scopolamine)
- Chlorpromazine
- Drugs affecting liver enzymes that remove propranolol from your body (such as cimetidine, St. John's wort, certain SSRI antidepressants including fluoxetine/paroxetine/fluvoxamine, HIV protease inhibitors including ritonavir, rifamycins including rifabutin)
- Epinephrine
- Fingolimod
- Haloperidol
- Mefloquine
- Rizatriptan
- Theophylline
- Thioridazine
- Thyroid hormones (such as levothyroxine)
- Warfarin
- Other drugs to treat high blood pressure (such as clonidine, hydralazine, methyldopa, reserpine)
- Other heart medications (such as digoxin, disopyramide, propafenone, quinidine)
Integrative Programs, Protocols and Medical Systems
BCCT advisor Dwight McKee, MD, an integrative oncologist and co-author of After Cancer Care, February 20, 2017:
“I've advocated for propranolol (which seems to work the best compared with more 'modern' beta blockers), implemented as soon as possible after diagnosis, since a new diagnosis of cancer is a highly stressful event, and we have both experimental and clinical evidence that stress acts as a tumor promoter, although it doesn't appear to be involved in the initiation of malignancy.
I have recommended propranolol for anyone diagnosed with cancer who is experiencing high levels of stress.
Dwight McKee, MD
I have recommended propranolol for anyone diagnosed with cancer who is experiencing high levels of stress from their diagnosis, and all of the logistics involved in seeing different doctors, and making treatment decisions often with a sense of time pressure (the psychological emergency of a cancer diagnosis). It takes time for people to learn and become proficient with stress management techniques, so I see propranolol as “ training wheels” until they are in calmer waters and well on their way to practicing an “ anticancer lifestyle”, which includes learning and practicing stress management techniques.
Read more
A typical dose and schedule would be 40 mg twice daily, but I would start with 10 mg once a day, then 10 mg twice a day and increase by 10 mg every few days (as tolerated) up to 40 mg twice daily, if that dose and schedule is well tolerated. Some people will get dizzy from low blood pressure from too high an initial dose, so it‘s always a good idea to start low and increase by 10 mg every few days. I would use the same approach for a patient with angiosarcoma.
The older beta blockers seem to work better for this application than the newer ones. Contraindications are severe asthma (propranolol can block the rescue effects of adrenaline) and very low baseline blood pressure. People with high blood pressure can start with higher dose, even at 40 mg twice daily. If they are taking another beta-blocker, I would suggest they work with a doctor in converting over to Inderal.
Non-cancer Uses of Propranolol
Propranolol is approved by the FDA and commonly used to treat the following:
- Heart disease: angina, cardiac arrhythmia, atrial fibrillation, survival of acute myocardial infarction (heart attack), hypertrophic subaortic stenosis, hypertension
- Essential tremor in the head, arms and legs
- Prevention of migraine or variceal bleeding
Propranolol is also used off-label for a number of conditions including these:
- Aggression associated with brain injury
- Anxiety
- Hemorrhage
- Sepsis
BCCT has not reviewed the effectiveness of this therapy for non-cancer uses.
|
- Cote J. Could a common and inexpensive heart medicine (beta-blockers) help cancer patients live longer? Cancer Prevention and Treatment Fund. Viewed October 31, 2017; Weberpals J, Jansen L et al. Pre- and post-diagnostic β-blocker use and lung cancer survival: a population-based cohort study. Scientific Reports. 2017 Jun 6;7(1):2911.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Choi CH, Song T et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. Journal of Cancer Research and Clinical Oncology. 2014 Jul;140(7):1179-88.
- Pasquier E, André N et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine. 2016 Apr;6:87-95.
- Botteri E, Munzone E et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Research and Treatment. 2013 Aug;140(3):567-75.
- Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011 Jul 1;29(19):2635-44.
- Childers WK, Hollenbeak CS, Cheriyath P. β-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clinical Breast Cancer. 2015 Dec;15(6):426-31.
- Cardwell CR, Pottegård A et al. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Research. 2016 Dec 1;18(1):119; Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K. Is beta-blocker use beneficial in breast cancer? A meta-analysis. Oncology. 2017;92(5):264-268.
- Shaashua L, Shabat-Simon M et al. Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. Clinical Cancer Research. 2017 Aug 15;23(16):4651-4661.
- Wittayanukorn S, Qian J et al. Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or β-blockers in older adults with breast cancer. American Journal of Clinical Oncology. 2018 Sep;41(9):909-918; Fanous I, Dillon P. Cancer treatment-related cardiac toxicity: prevention, assessment and management. Medical Oncology. 2016 Aug;33(8):84; Yun S, Vincelette ND, Abraham I. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgraduate Medical Journal. 2015 Nov;91(1081):627-33.
- Hiller JG, Cole SW et al. Preoperative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a phase II randomized trial. Clinical Cancer Research. 2020;26(8):1803-1811.
- Wang HM, Liao ZX et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Annals of Oncology. 2013 May;24(5):1312-9.
- Weberpals J, Jansen L et al. Pre- and post-diagnostic β-blocker use and lung cancer survival: a population-based cohort study. Scientific Reports. 2017 Jun 6;7(1):2911.
- Watkins JL, Thaker PH et al. Clinical impact of selective and nonselective beta blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 1;121(19):3444-51.
- Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecologic Oncology. 2012 Nov;127(2):375-8.
- Hefner J, Csef H et al. The clinical relevance of beta blockers in ovarian carcinoma: a systematic review. Geburtshilfe und Frauenheilkunde. 2016 Oct;76(10):1050-1056.
- Heitz F, Hengsbach A et al. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecologic Oncology. 2017 Jan;144(1):181-186.
- Bhattacharyya GS, Babu KG et al. Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel. Journal of Clinical Oncology. 2015 Jan;33(3_suppl):302-302.
- Assayag J, Pollak MN, Azoulay L. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. European Journal of Cancer. 2014 Nov;50(16):2838-45.
- Choy C, Raytis JL et al. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative β-blockade. Oncology Reports. 2016 Jun;35(6):3135-42.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Pasquier E, Ciccolini J et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011 Oct;2(10):797-809.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Bijman JT et al. Modulation of placental alkaline phosphatase activity and cytokeratins in human HN-1 cells by butyrate, retinoic acid, catecholamines and histamine. British Journal of Cancer. 1987;56(2):127–32; Schuller HM, Cole B. Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line. Carcinogenesis. 1989;10(9):1753–5; Lin X et al. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. Hepatogastroenterology. 2012;59(114):584–8.
- Sood AK, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clinical Cancer Research. 2006;12(2):369–75; Yang EV, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Research. 2006;66(21):10357–64; Kim-Fuchs C et al. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behavior, and Immunity. 2014;40:40–7; Liao X et al. The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncology Reports. 2010;24(6):1669–76; Barbieri A et al. The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. International Journal of Oncology. 2015;47(2):527–34; Annabi B et al. Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells. OncoTargets and Therapy. 2010;3:219–26.
- Zhang D et al. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist’s anticancer effect in pancreatic cancer cell. Pancreas. 2009;38(1):94–100; Chin C-C et al. Selective β2-AR blockage suppresses colorectal cancer growth through regulation of EGFR-Akt/ERK1/2 signaling, G1-phase arrest and apoptosis. Journal of Cell Physiology. 2016;231(2):459–72; Wolter JK et al. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget. 2014;5(1):161–72.
- Lee J et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clinical Cancer Research. 2009;15(8):2695–702; Shan T et al. β2-AR-HIF-1α: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis. Current Molecular Medicine. 2013;13(6):1023–34.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Hefner J, Csef H et al. The clinical relevance of beta blockers in ovarian carcinoma: a systematic review. Geburtshilfe und Frauenheilkunde. 2016 Oct;76(10):1050-1056.
- Rico M, Baglioni M et al. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017 Jan 10;8(2):2874-2889.
- Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews. Clinical Oncology. 2015 Apr;12(4):213-26.
- Lee JW, Shahzad MM et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clinical Cancer Research. 2009 Apr 15;15(8):2695-702.
- Choy C, Raytis JL et al. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative β-blockade. Oncology Reports. 2016 Jun;35(6):3135-42.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Ma Y, Bai F et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019 Apr 25;20(1):18.
- Wittayanukorn S, Qian J et al. Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or β-blockers in older adults with breast cancer. American Journal of Clinical Oncology. 2018 Sep;41(9):909-918; Fanous I, Dillon P. Cancer treatment-related cardiac toxicity: prevention, assessment and management. Medical Oncology. 2016 Aug;33(8):84; Yun S, Vincelette ND, Abraham I. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgraduate Medical Journal. 2015 Nov;91(1081):627-33.
- Lindgren ME, Fagundes CP et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013 Aug;22(8):1889-94.
- Bhattacharyya GS, Babu KG et al. Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel. Journal of Clinical Oncology. 2015 Jan;33(3_suppl):302-302.
- Hyltander A, Daneryd P, Sandström R, Körner U, Lundholm K. Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. European Journal of Cancer. 2000 Feb;36(3):330-4.
- Lindgren ME, Fagundes CP et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013 Aug;22(8):1889-94.
- Chang PY, Huang WY et al. Propranolol reduces cancer risk: a population-based cohort study. Medicine (Baltimore). 2015 Jul;94(27):e1097.
- Botteri E, Munzone E et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Research and Treatment. 2013 Aug;140(3):567-75.
- Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K. Is beta-blocker use beneficial in breast cancer? A meta-analysis. Oncology. 2017;92(5):264-268; Childers WK, Hollenbeak CS, Cheriyath P. β-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clinical Breast Cancer. 2015 Dec;15(6):426-31.
- De Giorgi V, Grazzini M et al. Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol. 2017 Sep 28.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Hefner J, Csef H et al. The clinical relevance of beta blockers in ovarian carcinoma: a systematic review. Geburtshilfe und Frauenheilkunde. 2016 Oct;76(10):1050-1056.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Tarr AJ et al. β-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption. Brain, Behavior, and Immunity. 2012;26(8):1226–38.
- Watkins JL, Thaker PH et al. Clinical impact of selective and nonselective beta blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 1;121(19):3444-51; Merville S. Betting on Beta Blockers. The University of Texas MD Anderson Cancer Center. Summer 2014. Viewed October 31, 2017.
- Kang F, Ma W et al. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2. Journal of Nuclear Medicine. 2014 Mar;55(3):439-45.
- Rivero EM, Piñero CP et al. The β 2-adrenergic agonist salbutamol inhibits migration, invasion and metastasis of the human breast cancer MDA-MB- 231 cell line. Current Cancer Drug Targets. 2017;17(8):756-766.
- Barbieri A, Bimonte S et al. The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. International Journal of Oncology. 2015 Aug;47(2):527-34.
- Fogari R, Zoppi A et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. Journal of Cardiovascular Pharmacology. 1990;16 Suppl 5:S76-80.
- Winniford MD, Huxley RL, Hillis LD. Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients with severe angina of effort. Journal of the American College of Cardiology. 1983 Feb;1(2 Pt 1):492-8.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.; Suzman MM. Propranolol in the treatment of anxiety. Postgraduate Medical Journal. 1976;52 Suppl 4:168-7; Anxieties.com. Beta Blockers. Viewed November 2, 2017.
- WebMD. Propranolol HCL. Viewed November 2, 2017.
- Pérez Piñero C et al. Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. British Journal of Pharmacology. 2012;166(2):721–36.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- Cote J. Could a common and inexpensive heart medicine (beta-blockers) help cancer patients live longer? Cancer Prevention and Treatment Fund. Viewed October 31, 2017; US Food and Drug Administration. Inderal® (propranolol hydrochloride) Tablets. November 2010. Viewed October 31, 2017.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680. Suzman MM. Propranolol in the treatment of anxiety. Postgraduate Medical Journal. 1976;52 Suppl 4:168-7; Anxieties.com. Beta Blockers. Viewed November 2, 2017.
View All References
More Information
This work is licensed under a